11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Carregando...
Citações na Scopus
722
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CAMERON, David
PICCART-GEBHART, Martine J.
GELBER, Richard D.
PROCTER, Marion
GOLDHIRSCH, Aron
AZAMBUJA, Evandro de
UNTCH, Michael
SMITH, Ian
GIANNI, Luca
Citação
LANCET, v.389, n.10075, p.1195-1205, 2017
Resumo
Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of comparing observation with two durations of trastuzumab treatment at a median follow-up of 11 years, for patients enrolled in the HERA (HERceptin Adjuvant) trial. Methods HERA (BIG 1-01) is an international, multicentre, open-label, phase 3 randomised trial of 5102 women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries between Dec 7, 2001, and June 20, 2005. After completion of all primary therapy (including, surgery, chemotherapy, and radiotherapy as indicated), patients were randomly assigned (1: 1: 1) to receive trastuzumab for 1 year (once at 8 mg/kg of bodyweight intravenously, then 6 mg/kg once every 3 weeks) or for 2 years (with the same dose schedule), or to the observation group. Primary endpoint is disease-free survival, and analyses are in the intention-to-treat population. Hazard ratios (HRs) were estimated from Cox models, and survival curves were estimated by the Kaplan-Meier method. Comparison of 2 years versus 1 year of trastuzumab is based on 366-day landmark analyses. This study is registered with ClinicalTrials.gov (NCT00045032). Findings Of the 5102 women randomly assigned in the HERA trial, three patients had no evidence of having provided written informed consent to participate. We followed up the intention-to-treat population of 5099 patients (1697 in observation, 1702 in 1-year trastuzumab, and 1700 in 2-years trastuzumab groups). After a median follow-up of 11 years (IQR 10.09-11.53), random assignment to 1 year of trastuzumab significantly reduced the risk of a disease-free survival event (HR 0.76, 95% CI 0.68-0.86) and death (0.74, 0.64-0.86) compared with observation. 2 years of adjuvant trastuzumab did not improve disease free-survival outcomes compared with 1 year of this drug (HR 1.02, 95% CI 0.89-1.17). Estimates of 10-year disease-free survival were 63% for observation, 69% for 1 year of trastuzumab, and 69% for 2 years of trastuzumab. 884 (52%) patients assigned to the observation group selectively crossed over to receive trastuzumab. Cardiac toxicity remained low in all groups and occurred mostly during the treatment phase. The incidence of secondary cardiac endpoints was 122 (7.3%) in the 2-years trastuzumab group, 74 (4.4%) in the 1-year trastuzumab group, and 15 (0.9%) in the observation group. Interpretation 1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival, compared with observation. 2 years of trastuzumab had no additional benefit.
Palavras-chave
Referências
- Bianchini G, 2014, LANCET ONCOL, V15, pE58, DOI 10.1016/S1470-2045(13)70477-7
- Chan A, 2016, LANCET ONCOL, V17, P367, DOI 10.1016/S1470-2045(15)00551-3
- COX DR, 1972, J R STAT SOC B, V34, P187
- de Azambuja E, 2014, LANCET ONCOL, V15, P1137, DOI 10.1016/S1470-2045(14)70320-1
- de Azambuja E, 2014, J CLIN ONCOL, V32, P2159, DOI 10.1200/JCO.2013.53.9288
- Gianni L, 2016, LANCET ONCOL, V17, P791, DOI 10.1016/S1470-2045(16)00163-7
- Gianni L, 2011, LANCET ONCOL, V12, P236, DOI 10.1016/S1470-2045(11)70033-X
- Goldhirsch A, 2013, LANCET, V382, P1021, DOI 10.1016/S0140-6736(13)61094-6
- Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523
- Kalbfleisch JD, 2002, STAT ANAL FAILURE TI, p[193, 247]
- KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
- Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868
- Piccart-Gebhart M, 2016, J CLIN ONCOL, V34, P1034, DOI 10.1200/JCO.2015.62.1797
- Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
- Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
- Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383
- Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2
- Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513